Pfizer Asks Supreme Court To Rule Whether Patient Drug Cost Program Is A Kickback
WASHINGTON, D.C. — Pfizer Inc. has asked the U.S. Supreme Court to review an appeals court ruling that a patient assistance program for a $225,000-a-year heart drug violates the Anti-Kickback Statute...To view the full article, register now.
Already a subscriber? Click here to view full article